The generation of a robust anti-tumor response relies on dendritic cells (DCs), professional antigen-presenting cells which must first recognize tumor antigens and damage-associated molecular patterns (DAMP) within the TIME via pattern-recognition receptors, and then process the antigens and migrate to the draining lymph node, where they present tumor antigen peptides to both CD4+ and CD8+ T-cells [27]. This evidence concerns the gene CD8A and neoplasm.